title: Nanoencapsulation in lipid-core nanocapsules controls mometasone furoate skin permeability rate and its penetration to the deeper skin layers.
abstract: OBJECTIVE
  The influence of nanoencapsulation of mometasone furoate (MF) in poly(ε-caprolactone) lipid-core nanocapsules (LNC) on its in vitro human skin permeation and penetration was evaluated.
  
  
  METHODS
  Semisolid formulations were prepared by increasing the viscosity of LNC using a carbomer (Carbopol(®) Ultrez at 0.5% w/v). Two complementary techniques (the static Franz diffusion cell model and the Saarbrücken penetration model) were used to evaluate skin permeation/penetration.
  
  
  RESULTS
  The drug release rate was decreased by nanoencapsulation. The skin permeability of MF was controlled by the nanoencapsulation as well as by increasing the viscosity. Furthermore, the formulation containing the nanoencapsulated MF controlled the amount of drug reaching the deeper skin layers without changing its accumulation in the stratum corneum.
  
  
  CONCLUSIONS
  This formulation is suitable for prolonged treatment of skin disorders which should avoid systemic absorption.
authors.affiliation: Department of Pharmaceutics and Pharmaceutical Technology, University of Valencia, Valencia, Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Melero
authors.forename: Aline
authors.initials: A
authors.lastname: Ferreira Ourique
authors.forename: Silvia
authors.initials: S
authors.lastname: Stanisçuaski Guterres
authors.forename: Adriana
authors.initials: A
authors.lastname: Raffin Pohlmann
authors.forename: Claus-Michael
authors.initials: CM
authors.lastname: Lehr
authors.forename: Ruy Carlos
authors.initials: RC
authors.lastname: Ruver Beck
authors.forename: Ulrich
authors.initials: U
authors.lastname: Schaefer
mesh_terms: D006801:Humans; D008055:Lipids; D000068656:Mometasone Furoate; D053769:Nanocapsules; D010316:Particle Size; D010539:Permeability; D011091:Polyesters / Q000008:administration & dosage; D011244:Pregnadienediols / Q000008:administration & dosage / Q000493:pharmacokinetics*; D012867:Skin / Q000378:metabolism*; D012869:Skin Absorption
chemical_list: D008055:Lipids; D053769:Nanocapsules; D011091:Polyesters; D011244:Pregnadienediols; D000068656:Mometasone Furoate; C016240:polycaprolactone